OBJECTIVES: Ipilimumab is licensed for the treatment of adults with advanced (unresectable or metastatic) malignant melanoma. It was approved for reimbursement in Ireland in 2012, through the Oncology Drug Management System (ODMS). The ODMS was introduced by the National Cancer Control programme in July 2012. The scheme allows direct hospital reimbursement for approved high cost anti-cancer drugs for individual patients. Drugs must be prescribed for approved indications according to license informed protocols. The online based system is designed to collect information from hospitals (26 nationally) in relation to patient demographic data, cancer drug use and spending. This data is maintained by the payer (Primary Care Reimbursement Service (PCRS)). The objective of this study is to examine this real world data of patients treated with ipilimumab.  METHODS: The PCRS extracted data on all patients who had received ≥1 dose of ipilimumab ( June 2012 - May 2015) in the public hospital setting through the ODMS. Patient data included patient demographics, the quantity of ipilimumab supplied and the reimbursement claim data. The National Centre for Pharmacoeconomics analysed this anonymised data.  Kaplan-Meier survival curves were constructed using the Tierney et al methodology.  Survival data was extrapolated using the Hoyle and Henley methodology. RESULTS: A total of 205 patients who had received ≥1 dose ipilimumab over the period of analysis were identified. The mean age of the cohort was 60.4 years (SD ±14) and 58.5% were male. All 4 cycles of ipilimumab were received by 59% of patients. Seven patients were re-treated with the drug. Empirical and extrapolated real world survival data were compared to clinical trial evidence. CONCLUSIONS: The analysis provides real world survival outcomes for patients with advanced malignant melanoma treated with ipilimumab in Ireland. Examination of this evidence is prudent in advance of the launch of the PD1 inhibitors for malignant melanoma.